Current | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Applied Biosystems Group and Celera Genomics Group Second Quarter FY 2003 Financial Results and Conference Call Scheduled for January 23, 2003

Norwalk, CT - January 08, 2003

Applera Corporation announced today that it will issue fiscal year 2003 second quarter results for Applied Biosystems Group (NYSE:ABI) and Celera Genomics Group (NYSE:CRA) on Thursday, January 23, 2003. Results are scheduled for release before the opening of trading on the New York Stock Exchange.

Tony L. White, Chief Executive Officer, Dennis L. Winger, Chief Financial Officer of Applera Corporation, and senior managers from the Corporation's businesses will lead a conference call the same day at 10:00 a.m. (EDT) to discuss these results and to address management's financial outlook for the company. The call will be formatted to focus on each of the Applera businesses separately, approximately at the times indicated below, although the exact timing may be different as the call will proceed without pause between segments:

Applied Biosystems Group 10:00 a.m. (EDT)
Celera Diagnostics 10:45 a.m.
Celera Genomics Group 11:00 a.m.

During each segment, the management team will make prepared remarks and answer questions from securities analysts and investment professionals. Investors, securities analysts, representatives of the media and other interested parties who would like to participate should dial 706.634.4992 (code "Applera") at any time from 9:45 a.m. until the end of the call. This conference call will also be webcast. Interested parties who wish to listen to the webcast should visit www.applera.com and go to the "Investor Relations" section of the web site, or www.celera.com and go to the "Investor" section, or www.appliedbiosystems.com and go to the Investor Relations web page within the "About Us" section. A digital recording will be available approximately two hours after the completion of the conference call on January 23 until February 1, 2003. Interested parties should call 706.645.9291 and enter conference ID 7527541.

About Applera Corporation
Applera Corporation comprises two operating groups. The Applied Biosystems Group develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2002. The Celera Genomics Group, located in Rockville, MD, and South San Francisco, CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics. Celera intends to leverage its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets and diagnostic marker candidates, and to discover and develop new therapeutics. Its Celera Discovery Systemô online platform, marketed exclusively through the Applied Biosystems Knowledge Business, is an integrated source of information based on the human genome and other biological and medical sources. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostics products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at http://www.applera.com, or by telephoning 800.762.6923.


Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.